227 related articles for article (PubMed ID: 36789252)
1. Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art.
Laschtowitz A; Roderburg C; Tacke F; Mohr R
J Hepatocell Carcinoma; 2023; 10():181-191. PubMed ID: 36789252
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy and transplantation for hepatocellular carcinoma.
Tabrizian P; Abdelrahim M; Schwartz M
J Hepatol; 2024 May; 80(5):822-825. PubMed ID: 38253289
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons.
Luo Y; Teng F; Fu H; Ding GS
World J Gastrointest Oncol; 2022 Jan; 14(1):163-180. PubMed ID: 35116109
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?
Nevola R; Delle Femine A; Rosato V; Kondili LA; Alfano M; Mastrocinque D; Imbriani S; Perillo P; Beccia D; Villani A; Ruocco R; Criscuolo L; La Montagna M; Russo A; Marrone A; Sasso FC; Marfella R; Rinaldi L; Esposito N; Barberis G; Claar E
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296912
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors in liver transplant: a case series.
Rudolph M; Shah SA; Quillin R; Lemon K; Olowokure O; Latif T; Sohal D
J Gastrointest Oncol; 2023 Apr; 14(2):1141-1148. PubMed ID: 37201081
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular Carcinoma: The Role of Immunotherapy and Transplantation in the Era of Transplant Oncology.
Alghamdi S; Al-Hamoudi W
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958291
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular Carcinoma: The Evolving Role of Systemic Therapies as a Bridging Treatment to Liver Transplantation.
Saleh Y; Abu Hejleh T; Abdelrahim M; Shamseddine A; Chehade L; Alawabdeh T; Mohamad I; Sammour M; Turfa R
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893200
[TBL] [Abstract][Full Text] [Related]
8. Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: a narrative review.
Wang H; Qian YW; Dong H; Cong WM
Hepatobiliary Surg Nutr; 2024 Jun; 13(3):472-493. PubMed ID: 38911201
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives.
Su YY; Li CC; Lin YJ; Hsu C
Semin Liver Dis; 2021 Aug; 41(3):263-276. PubMed ID: 34130338
[TBL] [Abstract][Full Text] [Related]
10. Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma.
Zhang B; Yue J; Shi X; Cui K; Li L; Zhang C; Sun P; Zhong J; Li Z; Zhao L
BMJ Open; 2022 Sep; 12(9):e060955. PubMed ID: 36115673
[TBL] [Abstract][Full Text] [Related]
11. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
[TBL] [Abstract][Full Text] [Related]
12. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma.
Scheiner B; Roessler D; Phen S; Lim M; Pomej K; Pressiani T; Cammarota A; Fründt TW; von Felden J; Schulze K; Himmelsbach V; Finkelmeier F; Deibel A; Siebenhüner AR; Shmanko K; Radu P; Schwacha-Eipper B; Ebert MP; Teufel A; Djanani A; Hucke F; Balcar L; Philipp AB; Hsiehchen D; Venerito M; Sinner F; Trauner M; D'Alessio A; Fulgenzi CAM; Pinato DJ; Peck-Radosavljevic M; Dufour JF; Weinmann A; Kremer AE; Singal AG; De Toni EN; Rimassa L; Pinter M
JHEP Rep; 2023 Jan; 5(1):100620. PubMed ID: 36578451
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
Wang Z; Wang Y; Gao P; Ding J
Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular Carcinoma Immunotherapy.
Sperandio RC; Pestana RC; Miyamura BV; Kaseb AO
Annu Rev Med; 2022 Jan; 73():267-278. PubMed ID: 34606324
[TBL] [Abstract][Full Text] [Related]
16. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
Carloni R; Rizzo A; Ricci AD; Frega G; Federico AD; Palloni A; Marco MD; Gadaleta-Caldarola G; Brandi G
Future Oncol; 2022 Mar; 18(8):1023-1034. PubMed ID: 35109664
[TBL] [Abstract][Full Text] [Related]
17. Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.
Abdelrahim M; Esmail A; Saharia A; Abudayyeh A; Abdel-Wahab N; Diab A; Murakami N; Kaseb AO; Chang JC; Gaber AO; Ghobrial RM
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406533
[TBL] [Abstract][Full Text] [Related]
18. Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation.
Ouranos K; Chatziioannou A; Goulis I; Sinakos E
World J Transplant; 2022 Nov; 12(11):331-346. PubMed ID: 36437845
[TBL] [Abstract][Full Text] [Related]
19. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
Yin X; Wu T; Lan Y; Yang W
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35075482
[TBL] [Abstract][Full Text] [Related]
20. [The use of immuno-oncologic therapy in hepatocellular carcinoma in the context of liver transplantation. An interdisciplinary benefit/risk assessment].
Vogel A; Sterneck M; Vondran F; Waidmann O; Klein I; Lindig U; Nadalin S; Settmacher U; Tacke F; Schlitt HJ; Wege H
Z Gastroenterol; 2022 Feb; 60(2):184-191. PubMed ID: 34670296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
